Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more
Effector Therapeutics Inc (EFTR) - Total Assets
Latest total assets as of March 2024: $27.13 Million USD
Based on the latest financial reports, Effector Therapeutics Inc (EFTR) holds total assets worth $27.13 Million USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Effector Therapeutics Inc - Total Assets Trend (2019–2023)
This chart illustrates how Effector Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Effector Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Effector Therapeutics Inc's total assets of $27.13 Million consist of 96.6% current assets and 3.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.4% |
| Accounts Receivable | $52.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Effector Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Effector Therapeutics Inc's current assets represent 96.6% of total assets in 2023, an increase from 83.9% in 2019.
- Cash Position: Cash and equivalents constituted 72.4% of total assets in 2023, up from 67.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Effector Therapeutics Inc Competitors by Total Assets
Key competitors of Effector Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Effector Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Effector Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Effector Therapeutics Inc is currently not profitable relative to its asset base.
Effector Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.03 | 0.78 | 1.89 |
| Quick Ratio | 1.03 | 0.79 | 1.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $681.00K | $ -5.76 Million | $ 7.80 Million |
Effector Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Effector Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -29.3% |
| Total Assets | $20.54 Million |
| Market Capitalization | $933.26 USD |
Valuation Analysis
Below Book Valuation: The market values Effector Therapeutics Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Effector Therapeutics Inc's assets decreased by 29.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Effector Therapeutics Inc (2019–2023)
The table below shows the annual total assets of Effector Therapeutics Inc from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $20.54 Million | -29.35% |
| 2022-12-31 | $29.08 Million | -46.21% |
| 2021-12-31 | $54.06 Million | +223.61% |
| 2020-12-31 | $16.70 Million | +227.85% |
| 2019-12-31 | $5.09 Million | -- |